TRINITY BIOTECH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.63 USD | +4.49% |
|
+3.82% | -24.01% |
| May. 23 | Transcript : Trinity Biotech plc, Q1 2024 Earnings Call, May 23, 2024 | |
| May. 23 | Trinity Biotech plc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2022 | 74.78M | Sales 2023 | 56.83M | Capitalization | 16.39M |
|---|---|---|---|---|---|
| Net income 2022 | -41M | Net income 2023 | -24M | EV / Sales 2022 | 1.38 x |
| Net Debt 2022 | 65.62M | Net Debt 2023 | 63.74M | EV / Sales 2023 | 1.41 x |
| P/E ratio 2022 |
-0.81
x | P/E ratio 2023 |
-0.68
x | Employees | 380 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Trinity Biotech plc
More press releases
| 1 day | +4.49% | ||
| 1 week | +3.82% | ||
| Current month | -10.44% | ||
| 1 month | -10.93% | ||
| 3 months | -32.08% | ||
| 6 months | -20.49% | ||
| Current year | -24.01% |
1 week
1.53
1.74
1 month
1.492.08
Current year
1.493.35
1 year
1.495.50
3 years
1.4918.30
5 years
1.4934.11
10 years
1.49123.15
| Managers | Title | Age | Since |
|---|---|---|---|
John Gillard
CEO | Chief Executive Officer | 43 | 20-11-16 |
Ronan O'Caoimh
FOU | Founder | 68 | 92-05-31 |
Eibhlin Kelly
CTO | Chief Tech/Sci/R&D Officer | 40 | 15-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ronan O'Caoimh
FOU | Founder | 68 | 92-05-31 |
Jim Walsh
BRD | Director/Board Member | 65 | 95-09-30 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 22-10-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 1.63 | +4.49% | 31,303 |
| 24-05-22 | 1.56 | +0.65% | 12,414 |
| 24-05-21 | 1.55 | -1.90% | 7,916 |
| 24-05-20 | 1.58 | 0.00% | 15,734 |
| 24-05-17 | 1.58 | +0.64% | 3,798 |
Delayed Quote Nasdaq, May 23, 2024 at 03:59 pm EDT
More quotes
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
Calendar
2024-05-29
- Lytham Partners Spring Investor Conference
| 1st Jan change | Capi. | |
|---|---|---|
| -24.01% | 15.43M | |
| -5.86% | 12.11B | |
| -4.87% | 8.07B | |
| +5.47% | 5.67B | |
| +27.42% | 5.48B | |
| -9.89% | 4.12B | |
| -58.99% | 2.75B | |
| +8.97% | 2.62B | |
| -5.19% | 2.33B | |
| +21.58% | 2.11B |
- Stock Market
- Equities
- TRIB Stock
